Files for orphan drug designation of pramiracetam as an adjunct to electroshock therapy, start-up firm announces July 2. CNS acquired the drug from Warner-Lambert as part of strategy to help fund R&D by acquiring near-term or already marketed products in niche neuropsychiatric markets ("The Pink Sheet" May 27, T&G-14). The firm estimates more than 100,000 courses of electroshock therapy are given each year in the U.S. Pramiracetam Phase III trials are slated to begin in the next 12 months.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth